Docoh
Loading...

TPTX Turning Point Therapeutics

News

Pro users get this 30m faster
The Daily Biotech Pulse: Moderna Awaits Adcom Ruling On COVID-19 Booster Shot; Teligent Files For Chapter 11; CFO Transitions at Catalyst Biosciences, CRISPR; Lucid Diagnostics Debuts
14 Oct 21
Biotech, News, Penny Stocks, Guidance, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Turning Point Therapeutics, EQRx Announce Clinical Collaboration To Evaluate Elzovantinib In Combination With Aumolertinib In Patients With EGFR Mutant Met-Amplified Advanced Non-Small Cell Lung Cancer
13 Oct 21
News, FDA
Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, and EQRx, a new type of pharmaceutical company committed to
10 Biggest Price Target Changes For Tuesday
12 Oct 21
Price Target, Small Cap, Pre-Market Outlook, Analyst Ratings
Evercore ISI Group raised Lear Corporation (NYSE: LEA) price target from $170 to $220. Lear shares fell 0.3% to close at $167.76 on Monday.
HC Wainwright & Co. Maintains Buy on Turning Point, Lowers Price Target to $162
12 Oct 21
News, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Robert Burns maintains Turning Point (NASDAQ:TPTX) with a Buy and lowers the price target from $178 to $162.
Turning Point Therapeutics To Present Early Clinical Data For Repotrectinib From CARE Study Oct. 23
11 Oct 21
Biotech, News, FDA, General
Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that it will present early clinical data for
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2021
11 Oct 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
JMP Securities Downgrades Turning Point to Market Perform
11 Oct 21
News, Downgrades, Analyst Ratings
JMP Securities analyst Silvan Tuerkcan downgrades Turning Point (NASDAQ:TPTX) from Market Outperform to Market Perform.
Turning Point Reveals Early Repotrectinib Data In NTRK+ Advanced Solid Tumors
8 Oct 21
Biotech, News, Health Care, Movers, Trading Ideas, General
Turning Point Therapeutics Inc (NASDAQ: TPTX) announced early data from TRIDENT-1 Phase 1/2 study of its lead drug candidate repotrectinib.
Turning Point Therapeutics Presents TRIDENT-1 Study Clinical Data For Repotrectinib In NTRK+ Advanced Solid Tumors In Plenary Session At 2021 AACR-NCI-EORTC Conference
8 Oct 21
News, FDA, Events
Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the presentation of early clinical data from
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
8 Oct 21
Biotech, News, Penny Stocks, Guidance, Offerings, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7)
45 Biggest Movers From Yesterday
8 Oct 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Camber Energy, Inc.. (NYSE: CEI) shares surged 95.9% to close at $1.78 on Thursday after dipping over 40% on Wednesday. Camber Energy filed amended 8K showing financial statements of Viking.
12 Health Care Stocks Moving In Thursday's Intraday Session
7 Oct 21
Intraday Update, Markets, Movers
28 Stocks Moving In Thursday's Mid-Day Session
7 Oct 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers Camber Energy, Inc.. (NYSE: CEI) jumped 44.2% to $1.3102 after dipping over 40% on Wednesday. Camber Energy filed amended 8K showing financial statements of Viking.
Turning Point Shares Plunge After Highlighting Updated Data From Lead Program In Pretreated Lung Cancer Patients
7 Oct 21
Biotech, News, Health Care, Movers, Trading Ideas, General
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
7 Oct 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6)
Turning Point Therapeutics Presents Updated Preliminary Clinical Data For Repotrectinib And Elzovantinib At 2021 AACR-NCI-EORTC Conference And Provides Regulatory Updates
7 Oct 21
Biotech, News, Events, General
Repotrectinib Demonstrates Clinical Activity Across Multiple ROS1+ TKI-Pretreated NSCLC Cohorts, with Confirmed Objective Response Rates of 30-39 Percent in TRIDENT-1 Study Repotrectinib Demonstrates
The Week Ahead In Biotech (Oct. 3-9): ChemoCentryx FDA Decision, Conference Presentations, IPOs And More
3 Oct 21
Biotech, Earnings, News, Penny Stocks, Small Cap, FDA, IPOs, Top Stories, General
Biotech stocks came under pressure in the week ending Oct. 1, dragged by broader market weakness and the selling of vaccine stocks.
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
30 Sep 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
Stifel Initiates Coverage On Turning Point with Hold Rating, Announces Price Target of $75
30 Sep 21
News, Price Target, Initiation, Analyst Ratings
Stifel analyst Bradley Canino initiates coverage on Turning Point (NASDAQ:TPTX) with a Hold rating and announces Price Target of $75.
Turning Point Therapeutics Announces Early Clinical Data For Repotrectinib In NTRK Fusion-Positive Advanced Solid Tumors Selected For Late-Breaker Plenary Presentation At 2021 AACR-NCI-EORTC Conference
8 Sep 21
Biotech, News, FDA, General
Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced a late-breaker abstract of early clinical data by

Press releases

Pro users get this 30m faster
Turning Point Therapeutics and EQRx Announce Clinical Collaboration to Evaluate Elzovantinib in Combination with Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced Non-Small Cell Lung Cancer
13 Oct 21
Health Care, Press Releases
SAN DIEGO, Calif. and CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of
Turning Point Therapeutics to Present Early Clinical Data for Repotrectinib From the CARE Study in Pediatric and Young Adult Patients at SIOP 2021 Virtual Congress
11 Oct 21
Health Care, Press Releases, General
SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that
Turning Point Therapeutics Presents TRIDENT-1 Study Clinical Data for Repotrectinib in NTRK+ Advanced Solid Tumors in Plenary Session at 2021 AACR-NCI-EORTC Conference
8 Oct 21
News, Press Releases
Confirmed Objective Response Rate of 48 Percent in Patients with NTRK+ TKI-Pretreated Advanced Solid TumorsConfirmed Objective Response Rate of 62 Percent in NTRK+ TKI-Pretreated Advanced Solid Tumor Patients with
Turning Point Therapeutics Presents Updated Preliminary Clinical Data for Repotrectinib and Elzovantinib (TPX-0022) at 2021 AACR-NCI-EORTC Conference and Provides Regulatory Updates
7 Oct 21
News, Health Care, Press Releases, General
Repotrectinib Demonstrates Clinical Activity Across Multiple ROS1+ TKI-Pretreated NSCLC Cohorts, with Confirmed Objective Response Rates of 30-39 Percent in TRIDENT-1 StudyRepotrectinib Demonstrates Confirmed Objective
Zai Lab Partner Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With NTRK-Positive, TKI-Pretreated Advanced Solid Tumors
4 Oct 21
Health Care, Press Releases
SHANGHAI, China and SAN FRANCISCO, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688)) partner Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing
Turning Point Therapeutics Announces Additional Details for Three Data Presentations at the 2021 AACR-NCI-EORTC Conference
30 Sep 21
News, Press Releases
SAN DIEGO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced
Turning Point Therapeutics Announces Early Clinical Data for Repotrectinib in NTRK Fusion-Positive Advanced Solid Tumors Selected for Late-Breaker Plenary Presentation at 2021 AACR-NCI-EORTC Conference
8 Sep 21
News, Health Care, Press Releases
SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced a
Turning Point Therapeutics Reports Second-Quarter Financial Results, Provides Operational Updates
9 Aug 21
Press Releases
Phase 1/2 TRIDENT-1 Enrollment Reaches Approximately 300 Patients, Including More than 50 in the ROS1-Positive TKI-naïve NSCLC Cohort (EXP-1)TPX-0022 Granted Fast Track Designation in MET Amplified Advanced or Metastatic
Turning Point Therapeutics to Host Second Quarter 2021 Conference Call
28 Jul 21
News, Press Releases
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ:TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report second